Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Windtree Therapeutics Inc (WINT)

Windtree Therapeutics Inc (WINT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,879
  • Shares Outstanding, K 8,990
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,290 K
  • EBIT $ -26 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.64
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -47.70
  • Most Recent Earnings $-4.23 on 11/26/24
  • Next Earnings Date 11/28/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.92
  • Number of Estimates 1
  • High Estimate -0.92
  • Low Estimate -0.92
  • Prior Year -13.31
  • Growth Rate Est. (year over year) +93.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3173 +0.91%
on 12/20/24
0.6174 -48.14%
on 11/27/24
-0.1902 (-37.26%)
since 11/20/24
3-Month
0.3173 +0.91%
on 12/20/24
3.4600 -90.75%
on 09/23/24
-2.8098 (-89.77%)
since 09/20/24
52-Week
0.3173 +0.91%
on 12/20/24
14.7487 -97.83%
on 08/07/24
-12.9962 (-97.60%)
since 12/20/23

Most Recent Stories

More News
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference

WINT : 0.3202 (-1.48%)
Windtree Therapeutics Files New Patent Application for Istaroxime Derivatives Aimed at Reducing Acute Myocardial Arrhythmia Risk

Windtree Therapeutics files a new patent application for istaroxime derivatives aimed at reducing acute myocardial arrhythmia risk.Quiver AI SummaryWindtree Therapeutics, Inc. has announced the filing...

WINT : 0.3202 (-1.48%)
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

WINT : 0.3202 (-1.48%)
Windtree Therapeutics Engages New Growth Advisors to Explore Strategic Opportunities for Cardiovascular Portfolio

Windtree Therapeutics engages New Growth Advisors to explore strategic options for its cardiovascular portfolio, including potential asset sales or out-licensing.Quiver AI SummaryWindtree Therapeutics,...

WINT : 0.3202 (-1.48%)
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

WINT : 0.3202 (-1.48%)
Windtree Therapeutics Reports Positive Phase 2b Results for Istaroxime and Third Quarter 2024 Financials

Windtree Therapeutics reports positive results in istaroxime studies and addresses financial updates for Q3 2024.Quiver AI SummaryWindtree Therapeutics, Inc. reported positive developments for the third...

WINT : 0.3202 (-1.48%)
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

WINT : 0.3202 (-1.48%)
Windtree Announces Leadership Transition Plan With Industry Veterans

WINT : 0.3202 (-1.48%)
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong

WINT : 0.3202 (-1.48%)
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3

WINT : 0.3202 (-1.48%)

Business Summary

Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. The company's proprietary technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous...

See More

Key Turning Points

3rd Resistance Point 0.3592
2nd Resistance Point 0.3503
1st Resistance Point 0.3352
Last Price 0.3202
1st Support Level 0.3112
2nd Support Level 0.3023
3rd Support Level 0.2872

See More

52-Week High 14.7487
Fibonacci 61.8% 9.2359
Fibonacci 50% 7.5330
Fibonacci 38.2% 5.8301
Last Price 0.3202
52-Week Low 0.3173

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar